March 17, 2025
FDA grants orphan drug status for Korro Bio’s AATD therapy
The US Food and Drug Administration (FDA) has granted orphan drug designation for Korro Bio’s KRRO-110 to treat alpha-1 antitrypsin deficiency (AATD).